MolMed SpA restored a measure of confidence to European biotechnology by netting €50.1 million (US$76 million) in the sector's first IPO of this year. Shares will begin trading today on the Mercato Telematico Azionario, the electronic share-trading platform administered by Milan, Italy-based Borsa Italiana SpA. (BioWorld International)

InterMed, Cognis Enter Natural Products Screening Alliance

March 5, 2008

By Cormac Sheridan

MolMed Nets $76M in Europe's First Biotechnology IPO of 2008

March 5, 2008

By Cormac Sheridan

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...